The New England Journal of Medicine has recently published a study which showed that the safety in the long term use of bisphosphonate drugs, like Fosamax, for osteoporosis treatment may be in question.The study suggested that in two separate case theories there has been a link between prolonged bisphosphonate therapy and atypical fractures.There was one study which showed a number patients sustained low-energy non-vertebral fractures while receiving long-term alendronate therapy; three were fractures of the femoral shaft.
Also the study showed that bone biopsies in the patients showed evidence of severely suppressed bone turnover and fracture healing that was delayed or not there at all.Fosamax is actually suppress bone turnover and thus might be associated with accumulated micro-damage in bone in theory.
In the published study the editor states: “To our knowledge, no study has demonstrated microdamage accumulation in patients treated with bisphosphonates, and data from studies in animals remain difficult to interpret because supranormal doses of bisphosphonates are used. Nevertheless, the possibility that bisphosphonates alter bone strength with prolonged use appears to exist.”
The length of Fosamax use seems to be a factor that the study takes into account.The results of the study concluded that the patients who have been on Fosamax for an average time longer than five years were 37% more likely to suffer from atypical fractures than patients who have been on the drug for less time
Fosamax lawsuit plaintiffs may want to take notice of the results of this this study as it may provide the link between Fosamax and bone fractures they have been looking for.As Merck and the FDA has both gone on record stating that more information is needed to link Fosamax to these types of bone fractures.
However the conclusion of the researchers have also stated that they need more information to definitely link Fosamax to atypical bone fractures.In conclusion the editor of the study states: “In light of the limitations of our study, a prospective study is indicated. Although many possible explanations exist, patients with the unique radiographic pattern shown here may represent a subgroup of the population that is more susceptible to the effects of prolonged suppression of bone turnover. Additional studies are needed to characterize this subgroup and to establish a clear association between atypical fractures of the femur and prolonged bisphosphonate treatment.”
URL References:
nejm.org/doi/full/10.1056/NEJMc0707493
health.usnews.com/usnews/health/healthday/080319/fosamax-linked-to-unusual-femur-fractures.htm
